vs
牛津地产（IIPR）与IOVANCE BIOTHERAPEUTICS, INC.（IOVA）财务数据对比。点击上方公司名可切换其他公司
IOVANCE BIOTHERAPEUTICS, INC.的季度营收约是牛津地产的1.3倍（$86.8M vs $66.7M），IOVANCE BIOTHERAPEUTICS, INC.同比增速更快（17.7% vs -13.1%），过去两年IOVANCE BIOTHERAPEUTICS, INC.的营收复合增速更高（1001.6% vs -6.0%）
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
艾欧万斯生物治疗公司是一家总部位于加利福尼亚州圣卡洛斯的生物制药初创企业，专注于开发针对癌症的肿瘤浸润淋巴细胞（TIL）疗法，致力于为癌症患者提供创新型的免疫治疗方案。
IIPR vs IOVA — 直观对比
营收规模更大
IOVA
是对方的1.3倍
$66.7M
营收增速更快
IOVA
高出30.9%
-13.1%
两年增速更快
IOVA
近两年复合增速
-6.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.7M | $86.8M |
| 净利润 | $31.8M | — |
| 毛利率 | — | 67.4% |
| 营业利润率 | 47.8% | -84.7% |
| 净利率 | 47.8% | — |
| 营收同比 | -13.1% | 17.7% |
| 净利润同比 | -20.4% | — |
| 每股收益（稀释后） | $1.07 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IIPRIOVA
| Q4 25 | $66.7M | $86.8M | ||
| Q3 25 | $64.7M | $67.5M | ||
| Q2 25 | $62.9M | $60.0M | ||
| Q1 25 | $71.7M | $49.3M | ||
| Q4 24 | $76.7M | $73.7M | ||
| Q3 24 | $76.5M | $58.6M | ||
| Q2 24 | $79.8M | $31.1M | ||
| Q1 24 | $75.5M | $715.0K |
净利润IIPRIOVA
| Q4 25 | $31.8M | — | ||
| Q3 25 | $29.3M | $-91.3M | ||
| Q2 25 | $26.0M | $-111.7M | ||
| Q1 25 | $31.1M | $-116.2M | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $40.2M | $-83.5M | ||
| Q2 24 | $42.0M | $-97.1M | ||
| Q1 24 | $39.4M | $-113.0M |
毛利率IIPRIOVA
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
营业利润率IIPRIOVA
| Q4 25 | 47.8% | -84.7% | ||
| Q3 25 | 45.5% | -140.7% | ||
| Q2 25 | 45.9% | -189.8% | ||
| Q1 25 | 47.4% | -245.8% | ||
| Q4 24 | 54.7% | -117.5% | ||
| Q3 24 | 54.8% | -152.1% | ||
| Q2 24 | 53.1% | -327.6% | ||
| Q1 24 | 55.7% | -16464.6% |
净利率IIPRIOVA
| Q4 25 | 47.8% | — | ||
| Q3 25 | 45.3% | -135.3% | ||
| Q2 25 | 41.4% | -186.2% | ||
| Q1 25 | 43.3% | -235.5% | ||
| Q4 24 | 52.2% | — | ||
| Q3 24 | 52.6% | -142.7% | ||
| Q2 24 | 52.6% | -312.2% | ||
| Q1 24 | 52.3% | -15800.8% |
每股收益（稀释后）IIPRIOVA
| Q4 25 | $1.07 | — | ||
| Q3 25 | $0.97 | — | ||
| Q2 25 | $0.86 | $-0.33 | ||
| Q1 25 | $1.03 | $-0.36 | ||
| Q4 24 | $1.35 | $-0.24 | ||
| Q3 24 | $1.37 | $-0.28 | ||
| Q2 24 | $1.44 | $-0.34 | ||
| Q1 24 | $1.36 | $-0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $47.6M | $297.0M |
| 总债务越低越好 | $393.7M | — |
| 股东权益账面价值 | $1.8B | $698.6M |
| 总资产 | $2.4B | $913.2M |
| 负债/权益比越低杠杆越低 | 0.21× | — |
8季度趋势，按日历期对齐
现金及短期投资IIPRIOVA
| Q4 25 | $47.6M | $297.0M | ||
| Q3 25 | $41.9M | $300.8M | ||
| Q2 25 | $104.9M | $301.2M | ||
| Q1 25 | $133.3M | $359.7M | ||
| Q4 24 | $151.2M | $323.8M | ||
| Q3 24 | $172.4M | $397.5M | ||
| Q2 24 | $160.9M | $412.5M | ||
| Q1 24 | $173.5M | $356.2M |
总债务IIPRIOVA
| Q4 25 | $393.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IIPRIOVA
| Q4 25 | $1.8B | $698.6M | ||
| Q3 25 | $1.9B | $702.3M | ||
| Q2 25 | $1.9B | $698.5M | ||
| Q1 25 | $1.9B | $767.9M | ||
| Q4 24 | $1.9B | $710.4M | ||
| Q3 24 | $1.9B | $773.5M | ||
| Q2 24 | $1.9B | $768.5M | ||
| Q1 24 | $2.0B | $680.0M |
总资产IIPRIOVA
| Q4 25 | $2.4B | $913.2M | ||
| Q3 25 | $2.3B | $904.9M | ||
| Q2 25 | $2.3B | $907.4M | ||
| Q1 25 | $2.4B | $966.7M | ||
| Q4 24 | $2.4B | $910.4M | ||
| Q3 24 | $2.4B | $991.1M | ||
| Q2 24 | $2.4B | $964.3M | ||
| Q1 24 | $2.4B | $869.8M |
负债/权益比IIPRIOVA
| Q4 25 | 0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.2M | $-52.6M |
| 自由现金流经营现金流 - 资本支出 | — | $-61.9M |
| 自由现金流率自由现金流/营收 | — | -71.3% |
| 资本支出强度资本支出/营收 | — | 10.7% |
| 现金转化率经营现金流/净利润 | 6.22× | — |
| 过去12个月自由现金流最近4个季度 | — | $-336.2M |
8季度趋势，按日历期对齐
经营现金流IIPRIOVA
| Q4 25 | $198.2M | $-52.6M | ||
| Q3 25 | $45.6M | $-78.7M | ||
| Q2 25 | $48.4M | $-67.4M | ||
| Q1 25 | $54.2M | $-103.7M | ||
| Q4 24 | $258.4M | $-73.3M | ||
| Q3 24 | $64.9M | $-59.0M | ||
| Q2 24 | $64.2M | $-98.4M | ||
| Q1 24 | $71.6M | $-122.3M |
自由现金流IIPRIOVA
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
自由现金流率IIPRIOVA
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
资本支出强度IIPRIOVA
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
现金转化率IIPRIOVA
| Q4 25 | 6.22× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.86× | — | ||
| Q1 25 | 1.75× | — | ||
| Q4 24 | 6.46× | — | ||
| Q3 24 | 1.61× | — | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IIPR
暂无分部数据
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
